Marksans Pharma Limited (MARKSANS) Earnings Call Transcript & Summary

November 5, 2026

National Stock Exchange of India IN Health Care Pharmaceuticals earnings 59 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and welcome to the Marksans Pharma Q2 FY '27 earnings conference call, brought to you by Systematix Institutional Equities Limited. <<operator_script>> Kindly be aware that this call is being recorded. At this point, I'll turn things over to Mr. Vishal Manchanda of Institutional Equities Limited. Thanks, and the floor is yours, Mr. Manchanda.

Vishal Manchanda

analyst
#2

Thanks, Siddanth. I'm glad to welcome all of you, on behalf of Systematix Institutional Equities, to the Q2 FY '27 earnings call for Marksans Pharma. We're grateful to the management team at Marksans Pharma for letting us host today's call. Joining us now are senior leaders from the company: Mr. Mark Saldanha, who serves as Chairman and Managing Director, along with Mr. Jitendra Sharma, the Chief Financial Officer. At this point I'll pass things over to the company's management so they can give their opening remarks. The floor is yours, sir.

Mark Saldanha

executive
#3

Thank you, Vishal. Good afternoon, everyone. We appreciate you joining the Marksans Pharma Q2 and H1 FY '27 earnings conference call, and thank you for your ongoing interest in the company and for your support. I'm happy to report that this has been our strongest quarterly performance to date. Revenue from operations hit INR 940 crores in Q2, a record for us, which works out to 30.5% growth year on year. Just as important, profitability improved strongly alongside that growth. EBITDA rose 48.3% to INR 214 crores, and our EBITDA margin widened 274 basis points to 22.8%. The breadth and quality of this performance is especially encouraging. Our growth doesn't hinge on any single geography or acquisition. Momentum has been strong across Europe and the U.K., we continue to grow in North America, and greater traction in Australia and New Zealand contributed to these results. Even without the contribution from QliniQ, our underlying business grew approximately 25%. Meanwhile, we kept profitability healthy despite higher freight and input costs. That gives us confidence that the investments we've made in our portfolio, commercial capabilities and geographic expansions are translating into sustainable growth.

Mark Saldanha

executive
#4

What we're seeing in these results also shows how strong our business model is thanks to geographic diversification. North America remains a big, resilient base for us, and at the same time the U.K., Europe, and Australia and New Zealand are turning into growth engines that matter more and more. Having this diversification gives us several avenues for growth and lowers how much we depend on any one market. I'll start with the U.K. and Europe. Performance there has been especially strong. Revenue for this region rose 65% to roughly INR 405 crores. Many of you will remember that FY '26 was a fairly subdued year for our U.K. business. We spent that time on fundamentals, strengthening our portfolio, getting new product launches ready, and improving where we stand in the market. Those efforts are starting to show up in our performance now. Even if you strip out the contribution from the acquisitions, our business in the region grew 49% in Q2. Beyond the growth in our existing business, we're making headway on key strategic priorities, including building our own commercial infrastructure in major European markets. That brings us closer to customers and gives us tighter control over how we bring our portfolio to market. QliniQ in the Netherlands contributed about INR 84 crores in the first half, while ABC and Marksans GmbH are making our platform in Germany stronger.

Mark Saldanha

executive
#5

These businesses form key building blocks for our European strategy, and in time they ought to widen the opportunity for bringing in a broader portfolio and expanding our presence throughout the region. Now to North America, still our biggest market, which accounted for 44.8% of revenue. We posted record quarterly revenue of INR 421 crores — a rise of 8.7% year-on-year. That is an encouraging result given the economic conditions in the U.S. market. Our order book is still healthy and keeps growing, which gives us confidence that, looking ahead to the next few quarters, price erosion on our prescription products, even if it lands in single digits, leaves us extremely optimistic about the U.S. market. In Australia and New Zealand, revenue climbed 64% to roughly INR 101 crores. We are getting good traction from the approach we have taken to build a branded prescription business under Nova. Our Rx division is expanding at a strong rate, and the growth we are delivering in these markets now is well above what was achieved a year earlier. We are encouraged by this progress and stay positive about the opportunities that lie ahead. Our Rest of the World business was affected during the quarter by continuing geopolitical disruptions in the Middle East and other regions, which shifted the timing of some shipments in the region.

Mark Saldanha

executive
#6

What matters here is that this was mostly a matter of operations and timing, not any shift in the underlying opportunities in these markets. We're watching the situation closely, and as conditions return to normal, we expect shipments — activities to recover progressively. Looking into the second half and beyond, our priorities for growth are unchanged. We'll keep deepening our presence in the existing market, scale our new established urban platform, expand our product portfolio, and selectively enter markets where we see an attractive opportunity. A healthy order book, expanding commercial capabilities and a strong financial position give us confidence in our ability to sustain profitable growth. Importantly, we are pursuing these opportunities from a position of financial strength. Strong cash generation and a net cash balance give us the flexibility to keep investing in our product pipeline and commercial capabilities while selectively evaluating acquisitions that offer a compelling strategic and financial fit. We remain disciplined in capital allocation, focused on execution and committed to creating a sustainable long-term value. With that, I hand over to Jitendra to take you through the financial performance.

Jitendra Sharma

executive
#7

Thank you, sir, and good afternoon to all of you. I'll walk you through how we performed financially in the second quarter, and then cover the first half. Beginning with Q2, our total income came in at INR 958 crores, which is a year-on-year rise of 29.2%. Revenue from operations reached INR 940 crores, up 30.5% year-on-year and 11.8% quarter-on-quarter. Turning to the geographical breakdown, North America delivered INR 421 crores, which works out to 44.8% of revenue. The UK and Europe delivered INR 405 crores, or 43%, and Australia and New Zealand delivered INR 101 crores, or 10.7%, while the Rest of World delivered INR 14 crores, or 1.5%. Gross profit rose 33.6% year-on-year to INR 550 crores, which was ahead of revenue growth. Our gross margin improved 135 basis points year-on-year, reaching 58.5%. EBITDA grew 48.3% year-on-year to INR 214 crores. EBITDA margin expanded by 274 basis points to 22.8%, which is ahead of the 20% -- 21% guidance we gave for the year. In Q1, we benefitted from consuming lower cost inventory. However, we are now seeing inventory costs increase, and that moved gross margin to 58.5% from 59.1% in the prior quarter. Notably, freight costs have nearly doubled in the current environment. The higher freight contribution, roughly INR 20 crores, added to the sequential increase in other expenses.

Jitendra Sharma

executive
#8

Employee costs also rose a bit, by roughly INR 8 crores, as we keep building up the team and putting money into newer markets. On top of that, our German business took on initial start-up costs of a couple of crores while we get those operations ready for the next phase. Given all that, posting a record quarterly EBITDA and holding an EBITDA margin of 22.8% is especially heartening. It shows the operating leverage in our business, along with a better product and geography mix and disciplined execution across our markets. Profit before tax for the quarter came in at INR 194 crores, up 35.1% year-on-year. Profit after tax rose by 44.8% to INR 144 crores, with a net margin of 15%. On a sequential basis, profit after tax fell to INR 144 crores from INR 159 crores in Q1, mainly because of higher depreciation and amortization after we began amortizing acquisition-related intangible assets, lower other income as currency movements stabilized, and a higher effective tax rate of 25.8%. Turning to the first half performance. Total income was INR 1,825 crores, up 33.4%, while revenue from operations grew by 32.9% to INR 1,781 crores. Gross margin improved by 137 basis points to 58.8%, helped in part by the lower average cost of inventory consumed, particularly during Q1.

Jitendra Sharma

executive
#9

EBITDA rose 74.7%, reaching INR 427 crores, and the margin widened 574 basis points to 24%. Profit after tax climbed 92.5% to INR 303 crores, giving a net margin of 16.6%. Higher other income also gave a boost to PAT in the first half. Another key highlight of H1 was cash generation. Operations produced INR 322 crores in cash, versus INR 75 crores in the same period a year earlier. Cash conversion — operating cash flow as a percentage of EBITDA — went up to 75.2% from 30.7%. Following capital expenditure of INR 46 crores, free cash flow came to INR 275 crores. We're also continuing to make headway on working capital management. The working capital cycle came down to roughly 128 days in the first half of the year, from 138 days in FY '26. In H1, we put about INR 95 crores toward acquisitions and paid roughly INR 41 crores in dividends. Despite these outflows, our net cash position rose by INR 135 crores over the period. At September end, cash balance and current investments were INR 1,124 crores. Our net cash position thus came to INR 1,095 crores, and net worth was INR 3,367 crores.

Jitendra Sharma

executive
#10

Our return ratios have also gotten better in a meaningful way. Measured over a trailing 12-month period, return on capital employed rose to 24.7% from 18.7%, and return on equity went up to 18.6% from 13.6%. R&D expenditure for H1 came to 2.6% of revenue. In closing, the first half showed strong revenue and profitability growth, healthy cash conversion and ongoing gains in capital efficiency. Thank you. We're now happy to take your questions.

Operator

operator
#11

<<operator_script>> Our first question is from Ahmed Madha, who is with Unifi Capital.

Ahmed Madha

analyst
#12

Well done on a strong set of results and solid execution. First, regarding the U.S., when you look at growth on a constant currency basis, it's fairly low in the first half. How should we think about your ability to drive more volumes in the second half? And more broadly, what does the order book look like? There were some remarks about consumer sentiment in the U.S. How do you view the market and growth in the second half, and generally for the U.S. business?

Mark Saldanha

executive
#13

Seasonality is clearly the biggest factor. A big chunk of our portfolio is seasonal, and it leans toward the cold season, obviously. The cold season hasn't arrived yet — normally it comes in October, November, December; that's the season. That said, when we talk about sentiment, we're talking about geopolitical situations, inflation, crude oil, all of that, affecting affordability in the U.S., with costs rising, obviously. Medicines, I think, are literally the last thing on anyone's mind. Food and gas, obviously, become the top priority for everybody else. So all of that, combined with seasonality — I mean, we've grown somewhat and we'll keep growing in the U.S. market. We're quite optimistic about hitting our objectives. We still believe that within the next 3 years, we should get to a $300 million order book status when it comes to the U.S. So we remain very optimistic as far as the U.S. is concerned.

Ahmed Madha

analyst
#14

Our overall run rate is now approaching roughly INR 1,000 crores, likely by the next quarter or thereabouts, you get to that level. So when it comes to expanding capacity organically, how are you thinking about that? Clearly, we have plenty of cash on hand. So would we be entering a significant CapEx cycle next year or thereabouts?

Mark Saldanha

executive
#15

As I've mentioned before, our perspective stretches further out than just the near term. We genuinely think we're moving in the right direction, and we're putting in the work and progressing toward reaching INR 5,000 crores within the next 3 years, and potentially doubling revenue versus where we stood last year inside the next 5 years — around INR 6,000-odd crores. That's what we're driving toward. Naturally, that will require CapEx infusion for manufacturing infrastructure to back that growth phase. You're correct that right now we're trending at INR 1,000 crores a quarter — very close to INR 1,000 crores, though you could round it to INR 1,000 crores a quarter. That gives us some visibility toward a INR 4,000 crore mark. So at this point, INR 4,000 crores isn't what we're discussing. We're already planning for INR 5,000 crores. And for that, we're examining opportunities to expand our infrastructure — perhaps adding another manufacturing block or acquiring another plant. We're in active dialogue on both fronts.

Operator

operator
#16

Arun from Unifi Capital has the next question.

Arun Kumar

analyst
#17

Sir, nice work on those strong figures. Could you walk us through how revenue growth is shaping up in the remaining regions, especially the U.K.? Given that the U.K. had a sluggish base as last year's price war wrapped up starting in Q4, what kind of growth are you anticipating there? And at the total company level, how does — could you give us a quick briefing on that? Do you...

Mark Saldanha

executive
#18

So the U.K. looks very promising, Arun, and I have to say it has gotten past last year's sluggish revenue stream. We've brought in newer products, newer launches much like I've always said — sometimes you just have to wait for the business model to unfold. We had plenty of products in the pipeline. We have a lot of products under filing, under registration and under approval. So as and when those approvals do happen — and we expect quite a few approvals each quarter — they will unfold revenue streams, new revenue streams, new penetration of these molecules into the market. So the U.K. is looking promising, but also Europe, because we are now looking at Europe, both from a geography as well as from an expansion of our IPs that we have created. So we are exhaustively looking at creating those infrastructures to market our products across Europe. And we are seeing some good results, although it's just the start. It's been a couple of months since we are into Europe, but it's looking extremely promising. So if you ask me my outlook of the U.K. and Europe, they will still continue to grow over the next couple of years and will be very important geographies to hit our objectives of INR 6,000 crores.

Arun Kumar

analyst
#19

Understood, sir. Historically, second-half PAT has come in above the first half. And since Q3 matters so much for our products, should we expect that pattern to hold this year as well? Will H2 PAT exceed H1, considering that H1 has already gained from the cheaper cost inventory and from ForEx gains?

Mark Saldanha

executive
#20

That's a great question, Arun. As you correctly pointed out, H1 — the first quarter clearly gained from substantial low-cost growth, whereas due to crude oil and all of those factors, costs have risen. And as we continue drawing down our stocks, we essentially have to buy fresh inventory. We expect to be range bound across the year as a whole. As I've consistently committed, I think our revenue performance will keep growing, and I'm quite confident about us setting objectives. And I think our EBITDA should be pretty much within a range bound of 21%, 22%, whatever we delivered this year — this quarter. So I do see our overall EBITDA sitting in that same range. On PAT — regarding PAT, I think aside from provisions for different taxations and depreciation, our PAT will be pretty much in line with what is expected.

Operator

operator
#21

Our following question is from Saksham Tyagi with Nestwell Advisory.

Analyst

analyst
#22

I’d like to start with one question: your investor presentation says Europe will be the main growth engine in the quarters ahead. I was hoping you could give some insight into that. How exactly will Europe serve as that key growth driver in the coming quarters?

Mark Saldanha

executive
#23

Since the pace has been quite slow today, we’re putting a lot of effort into essentially bringing in revenue. So all of these will contribute to both of our revenue streams, and that wasn’t included last year. So it definitely is contributing as a growth driver right now. So where Europe is concerned, we are literally beginning from 0. Over the next 3 years, I do see Europe developing very well and becoming a very prominent player — a prominent contributor to our overall set of objectives, as I mentioned earlier to Arun.

Analyst

analyst
#24

All right, then it could be as long as 3 years before those visible changes show up, correct?

Mark Saldanha

executive
#25

So look, some shifts are already visible. They might be modest at present, yet each year they'll expand. And we are indeed witnessing expansion in ABCnow. We're also seeing expansion in what — even within QliniQ, the company we have in the Netherlands. So — and beyond that, we have — we're currently examining and investigating additional M&As across Europe, and it's our hope to wrap up a few of them eventually, ideally inside the coming 12 months.

Analyst

analyst
#26

Alright, sir, got it. Now, sir, my next question relates to expansion. We're targeting an increase in Indian capacity up to 16 billion units per annum. So I'd just like to understand how we're going to get there, and how long that will take?

Mark Saldanha

executive
#27

I think the expansion is going to come in 2 folds. One is inside our own facility, within the infrastructure we have at the Teva plant — we're planning to add a couple of blocks there to expand dosage forms, plus some capacity debottlenecking. But we're also looking at expanding or acquiring a plant, which would give us more of — which would basically fuel more potential for revenue as well as volumes, which is what's needed. So right now we're in dialogue with 2 companies, but nothing concrete. But we're basically looking at expanding our manufacturing capabilities, hopefully, maybe — which we probably need a year down the line or so, immediate a bit, but maybe a year, 1.5 years down the line.

Analyst

analyst
#28

Alright, so do you have any expected timeline for that?

Mark Saldanha

executive
#29

My answer would most likely be 12 months.

Analyst

analyst
#30

Sir, one final question. Now that you hold the entire 100% stake in Access Healthcare in Dubai, could you shed some light on how that's performing? What contribution should we expect from it? And I'd also like to ask whether any further acquisitions are planned in the UAE region?

Mark Saldanha

executive
#31

Right now, we’re keeping an eye on the geopolitical situation. There are no M&As or acquisitions that we have planned in the Middle East. I believe Access Healthcare is holding up well at the moment, especially when you consider what it has been through for the full year. The war has had an effect on the Middle East, but we remain very profitable. It is still producing enough cash, even though revenue is extremely small relative to our overall turnover. But it is — we are working — again, within the scenarios, we are focused on growing our pipeline by 10 folds. So we are busy working on filing products and trying to expand that basket as early as possible.

Operator

operator
#32

Our following question is from Mihir Buha with Integrative Ventures and Partnerships.

Analyst

analyst
#33

Nice work on the solid quarters. I’ve got a couple of questions. The first one concerns volume growth—what was the volume like in this quarter across geographies?

Mark Saldanha

executive
#34

The volume is going to be robust. It really hinges on which market you mean — are you asking about India, or are you asking about the global picture? From every angle, volume ought to be robust. That said, on seasonality, we're looking for a solid winter and keeping our fingers crossed for it. Typically, though, Q3 tends to be our stronger quarter. So our hope is that we'll see healthy volumes.

Jitendra Sharma

executive
#35

So look at our overall growth — across the first half of this year, revenue is up 32.9%, and a big portion of that came purely from volume growth.

Analyst

analyst
#36

Understood. And could you break out the split between Rx and OTC for both this quarter and H1?

Mark Saldanha

executive
#37

Jiten?

Jitendra Sharma

executive
#38

Yeah, it was pretty much along the same lines. I'd say somewhere between 70% to 75% — roughly 75% OTC, with 25% being Rx.

Operator

operator
#39

Our following question is from Sandeep N. at MoneyGrow Assets.

Analyst

analyst
#40

With that sizable cash position on the balance sheet, is management looking at any sort of share repurchase plan or any acquisition? I'd just like to hear more on the capital allocation side.

Mark Saldanha

executive
#41

Yes, Sandeep, we're putting a fair bit of capital to work on 2 fronts. The first is clearly CapEx, and the second is M&As. We've been talking with companies, and those conversations are ongoing. Growth in Europe is what we're aiming to fuel. So we do see a couple more M&As possibly coming up across Europe. That said, the size could vary. Some might be small, others could be bigger, but we're seeking opportunities to grow, and that's the reason the funds are set aside so we can close those M&As. Until then, we're now looking at buying facilities in India, which would likely require a fair amount of cash to be deployed there from those funds. Buyback always remains an option — we've discussed it and will keep evaluating, and whenever we feel nothing else is happening, that could also be a possibility.

Operator

operator
#42

<<operator_script>> Our following question is from Harshil with ASK Wealth Advisors.

Analyst

analyst
#43

Thanks for the kind words about the numbers. Sir, I actually missed what you said about the U.S. market at the start, so I wanted to ask how we should think about that market, particularly given that we have mid-single-digit price erosion at play, which I believe may also be the case going forward. But overall, in terms of growth prospects and the outlook, how should it look for the second half and probably as we move into FY '28? Do we have any launches, like a certain number of launches signed up? And any comment you could offer on this would be helpful.

Mark Saldanha

executive
#44

We file ANDAs annually—that's an ongoing process. I'm hoping that within the coming year—over the next couple of months through March—we'll submit another 5 or 6 ANDAs. So it's a continuous effort, correct? We keep pursuing that path. Our product portfolio is expanding across every direction. We're fairly optimistic about the U.S. market. I realize geopolitically things were somewhat—somewhat of a mess because of everything that arose, yet there's a silver lining. So we're anticipating positive developments. We're anticipating corrective steps being implemented. The midterm elections have finished. So I'm fairly confident the U.S. market will remain a growth driver. I don't believe we need to assess it quarter by quarter. I think we should view it over the medium to long term, since substantial investments are being made in filings. So if you ask about my visibility for the coming 3 years, I think we're still heading toward a $300 million order book status within the coming 3 years.

Analyst

analyst
#45

So what you're basically saying is an order book of $300 million, more or less, across the next 2 to 3 years. Did I hear that right — is that correct?

Mark Saldanha

executive
#46

Yes, 3 years. I really think that over the next 3 years, our order book is going to grow from INR 225 crores to INR 300 crores.

Analyst

analyst
#47

All right. So that range would go from INR 225 crores up to INR 300 crores.

Mark Saldanha

executive
#48

Yes.

Analyst

analyst
#49

Alright, that's covered. Sir, one thing I wanted to raise with you concerns the ROW markets, given the geopolitical issues and all that are present there. You did mention during your opening remarks that you're keeping an eye on the situation. But is there any perspective you'd be willing to share — for instance, should the run rate hold as it did in the first half, or would you foresee any meaningful, or even slight, improvements there?

Mark Saldanha

executive
#50

I can see progress. For emerging markets, I still think we're performing pretty well. The first half was somewhat difficult since transportation took a hit. It had an impact — vessels, obviously, were all held up in the Red Sea, and everything there was chaotic when it came to logistics and the supply chain. That, I think, is gradually letting up. Even this month, in the last month, I do see better movement taking place. So I do see us recovering some of the ground we lost. Clearly, 6 months can't be made up, but we are recovering that lost ground. And I do believe that by the end of this year, hopefully, we'll be on track and get back to what we had envisaged for these markets. Our filings, or our product registration in these markets, remain a focus for us. So from our outlook, I mean, these are small bumps one has to get past because of situations beyond our control. But as I mentioned, we don't view it in quarters — we view it more from a long-term perspective.

Analyst

analyst
#51

Understood. So sir, regarding that roughly INR 25 crores per quarter run rate, is that something we could expect by the exit of FY '27 for the ROW markets, or is that still yet to be seen?

Mark Saldanha

executive
#52

It's hard to say — and again, all of us are hoping for something better. If you'd asked me that perhaps a quarter ago, I never imagined this war would go on so long. I was hoping the election pressure would bring it to an end before the vote, but who knows? That didn't happen. So I don't have a crystal ball for predicting geopolitical scenarios. But if things ease up, then I would say, yes, I mean, very close to INR 25 crores — maybe INR 20 crores to INR 25 crores is doable.

Operator

operator
#53

Mihir Damania with Fident AMC has the next question.

Mihir Damania

analyst
#54

To start off, my first question is about your mention that you're evaluating manufacturing assets in India. I was hoping for a bit more detail on precisely what type of assets you're considering. Historically, you've had a lot of strength in oral solid. So are we talking about similar kinds of assets that would add considerably more capacity? Or are we considering other modalities, perhaps moving into injectables, or possibly an asset for backward integration that would let you control costs better? I just wanted a little more clarity, since you indicated this could call for a substantial investment compared with all the other acquisitions you've made in the past.

Mark Saldanha

executive
#55

Right. For us at the moment, we're examining various dosage forms — not injectables — but we're looking at expanding dosage forms where we think we might see some capacity constraints perhaps 2 years out. And tablets and solid — sorry, solid oral could be part of that as well. So whatever we do, there's always solid oral involved. But yes, at this moment we're looking at expanding manufacturing capabilities.

Mihir Damania

analyst
#56

Backward integration — that isn't something you'd look at through API.

Mark Saldanha

executive
#57

When it comes to backward integration right now, considering what’s going on globally — we’re just not getting into that at this point.

Mihir Damania

analyst
#58

Then regarding depreciation, my second question — I was hoping for a little more detail, since sequentially the figure has climbed by roughly INR 6 crores to INR 7 crores even as gross doubled. I get that some intangible accounting is behind it, but I'd like to know whether that's the run rate we should assume, because for an acquisition of about INR 100 million — sorry, INR 100 crore — quarterly depreciation of INR 6 crore strikes me as a bit thin, so any extra detail on what depreciation to expect going forward would be very helpful.

Jitendra Sharma

executive
#59

Yes, Mihir. So starting this quarter, we've changed how we account for depreciation on intangible assets. Previously, we only tested those assets for impairment, and when making that impairment determination we assumed an indefinite useful life. Now, beginning this quarter, we're essentially treating the intangible asset as having a finite useful life, and we've begun depreciating it across 10 years. As for why this figure went up, we've also started recording depreciation on the intangible assets acquired from QliniQ and ABCnow. So a large part of this impact has come from those acquired intangible assets during this year as well.

Mihir Damania

analyst
#60

So is it fair to assume that's the run rate we'll be seeing over the next couple of quarters, or...

Jitendra Sharma

executive
#61

Yes.

Operator

operator
#62

<<operator_script>> Our following question is from Akshit Shetty with Manjit Kothari Family Office.

Analyst

analyst
#63

Great results — congratulations on that. First thing I'd like to ask about is U.S. OTC. In the Q2 FY '27 presentation, you spoke about your goal of doubling revenue from U.S. store brand OTC, and that this would be backed by a product pipeline that keeps expanding. One trend that stands out is that U.S. store brands are competing more and more on quality of product and innovation, not simply on price. So with that shift happening, is Marksans making its position stronger with the big retailers, going past simply being a manufacturer that is cost competitive? In other words, do you see a chance to turn into a strategic partner for these retailers in product development and in the supply chain?

Mark Saldanha

executive
#64

Yes. Akshit, we do, and we're already present with certain retailers. We've already established ourselves there in the spots where we discuss being first to market or discuss innovations. So we're always in conversations with them about innovation, and a good number of our retail partners turn to us for that kind of direction.

Analyst

analyst
#65

Understood. One more thing on Europe, if I may. During that same presentation, you pointed to what QliniQ in the Netherlands is contributing and to ABCnow in Germany being consolidated. So now that the European footprint is bigger, how do you intend to leverage that local distribution platform to bring in Marksans' current products and upcoming launches across several European markets? And do you expect this to open up a meaningful additional growth channel outside the existing U.K. business over the next 3 to 5 years, roughly?

Mark Saldanha

executive
#66

Yes — one word: yes, point one. Point two: the businesses we’ve bought are more centered on the specific country or geography where we acquired them. So when you say QliniQ, that’s the Netherlands; when you say ABC, that’s Germany. Those markets don’t represent all of Europe, but they do represent that country. And that’s where our inorganic growth strategy through M&As will keep going in other European countries. But they’ll contribute meaningful growth, both tangibly and intangibly, to what we do in Europe and to what we do in that specific country. And both countries have considerable potential, and Germany is a large market too.

Operator

operator
#67

After the operator's instructions, the next question comes from Pranav Gupta at Value Advisors.

Pranav Gupta

analyst
#68

I’ve got a couple of things I’d like to ask. First, Australia was up 64% year-on-year — I just want to get a sense of how much of that came from the Nova division. And how do we expect the next few quarters to look?

Mark Saldanha

executive
#69

Well, in Australia, 100% of it comes from Nova. We don't market anywhere else. So Nova is our subsidiary, and we market — that's our front end. So all our products are marketed through them. And we see Australia growing over the next 3 years to a $100 million subsidiary.

Pranav Gupta

analyst
#70

Got it. And as a quick follow-up, does our Europe goal for the top line — roughly INR 1,000 crores over 5 years — still hold?

Mark Saldanha

executive
#71

Yes.

Operator

operator
#72

Our following question is from Tanvi with Mera Capital.

Analyst

analyst
#73

First off, congratulations on a great set of numbers. I have a couple of questions. First, I wanted to know whether the INR 4,000 crores revenue target in about 2 years is still on track?

Mark Saldanha

executive
#74

My view is that we ought to reach INR 4,000 crores in the coming year. At present, we're running at a pace quite near INR 1,000 crores per quarter. So I'd say with plenty of comfort that we will get to INR 4,000 crores next year.

Analyst

analyst
#75

Okay. Second thing I wanted to ask — given that the U.K. market grew significantly following a flat, or flat, year in FY '26, is that sustainable?

Mark Saldanha

executive
#76

Yeah, it can be sustained. And given the product pipelines and the visibility we have on upcoming approvals, I genuinely think it will hold up. So growth will show. It's — I mean, revenue isn't going to double overnight, but it will grow quite substantially.

Analyst

analyst
#77

And finally, I just wanted to ask: given the net cash position right now, what's the dividend policy for FY '27?

Mark Saldanha

executive
#78

We need to assess that. There's a great deal on our plate at the moment. We haven't provided...

Jitendra Sharma

executive
#79

In the past, we've paid out roughly one-third of the free cash flow we generate as dividends. So generally speaking, it should stay consistent with that.

Operator

operator
#80

<<operator_script>> Our following question is from Arun with Unifi Capital.

Arun Kumar

analyst
#81

Let me ask about API costs. We've seen reports that API prices—paracetamol and ibuprofen in particular—are running at elevated levels. So have they peaked, begun to cool off, or do they remain elevated? And with Q2 gross margins at 58.5%, what margin should we expect for Q3 and Q4—closer to 58%, or the usual guidance of 55% to 56%?

Mark Saldanha

executive
#82

I'd likely keep it at 55%, 56%. Again, Arun, those things can shift very quickly — if crude prices fall, you'll see that number come down, and if the war gets worse, then obviously everything, all projections get thrown out the window. But we're fairly optimistic about the outlook. And this ties closely to what's happening with the midterm elections. So we do see things cooling off somewhat. And if you've looked at the last couple of days, crude has come down a bit. So I do think prices should cool down maybe within the next 30 days or so.

Arun Kumar

analyst
#83

Understood, sir. And should prices drop, would gross margin get there fast, or would the retailers come asking for price reductions? How does that typically play out, sir?

Mark Saldanha

executive
#84

Retailers aren't going to come asking us to lower prices, yet our gross margin is going to rise, clearly, or return to where it has historically been. Should we observe prices — raw material costs declining, obviously, raw material costs rise, then as I said, everything — every calculation needs to be — all of it must be redone. Still, we view this more optimistically and we're striving to hit our targets, since we recognize this is truly a near-term situation and it cannot last. And I mean, as I mentioned earlier during this call, I genuinely had hoped the war would have concluded prior to the midterm elections. It didn't. Yet I felt strongly that it ought to have, whatever the political reasons might be. Having said all that, we continue to hope it wraps up soon.

Arun Kumar

analyst
#85

Understood, sir. And a final question from me. I notice our lease liabilities have risen by INR 120 crores. Is that because of consolidating the acquisition, or have we entered into a new lease? Could you...

Jitendra Sharma

executive
#86

Yeah, we've signed a new lease over in the U.K., and that one originated from that geography.

Operator

operator
#87

Our next question is from Mr. Vishal Manchanda with Institutional Equities Limited.

Vishal Manchanda

analyst
#88

I'd like to get a sense of how much of your organic growth came from products already on the market versus new launches during the year. And on top of that, have you noticed any pricing moving up or down within our base portfolio?

Mark Saldanha

executive
#89

It really comes down to which regions we're talking about, Vishal. In the U.S., the bulk of our expansion is going to be organic, with a smaller piece coming from inorganic means. In the U.K., though, a fair amount will be driven by new launches. And in Europe, clearly, new launches will again account for a substantial share. Australia, too, will get a boost from the new launches still to come. All of this sits on top of what we're already doing. We're at a reasonable size and a reasonable base. So for sure, when it comes to our strategy of reaching new heights, new launches are extremely important.

Vishal Manchanda

analyst
#90

But in general, could you give some sense of what share of the growth typically comes from new launches — for instance, is it 20% of growth that new launches contribute, 10%, something like that...

Mark Saldanha

executive
#91

For the U.K., that figure will likely land at 20%. In Europe, though, it will probably come in higher — perhaps 50% or 60%. As for the U.S., it will likely be 10%.

Vishal Manchanda

analyst
#92

So when you think about where you're aiming these new launches, is it oral dosage forms — specifically oral solids — or are you looking to move into different dosage forms altogether?

Mark Saldanha

executive
#93

It is fairly well spread out, though injectables are not an area we participate in. So that is not the situation. But as things stand right now, orals are clearly the biggest part of the portfolio, as we speak. We are broadening it gradually, but no matter how much diversification we carry out, that will remain our largest segment.

Vishal Manchanda

analyst
#94

And are we seeing any price increases across our base portfolio?

Mark Saldanha

executive
#95

Are you referring to the finished product, or are you talking about...

Vishal Manchanda

analyst
#96

The finished goods.

Mark Saldanha

executive
#97

No, none of those things are happening.

Vishal Manchanda

analyst
#98

Okay. And has competitive intensity shifted at all? So are you noticing that competitive intensity is easing? Perhaps your competitors are dealing with cost challenges, and you're likely seeing competition decline over the years.

Mark Saldanha

executive
#99

Yes, we do see that. But whenever one thing comes down, another goes up, right? So we really don't — we don't focus much on any of that, because our growth comes from our own strengths and our strategy. We've been expanding very deliberately across our portfolio and in the geographies where we operate, we stand out, and we're getting good results from what we're doing. So — but that's just the nature of the beast. Competition will always be there. If we start watching who's doing what, we tend to get — bowed down by it. But we do — when we're choosing our products and deciding what we have to do, then of course we do our research to see how many players are in that market. Beyond that, we don't bother about what companies are basically doing on competition.

Vishal Manchanda

analyst
#100

And when it comes to what we're doing in R&D, have we zeroed in on any particular focus area, or are we aiming at products—basically just going after items where we don't currently have a presence? Is that how we're approaching new launches, or are there specific areas you'd have pinpointed?

Mark Saldanha

executive
#101

Right, so R&D is mostly centered on new niche molecules, to put it that way. And as we expand, we move into somewhat more complex molecules, which might involve Para IV challenges or first-to-market kinds of strategies. But all of this is simply part and parcel of our evolution into more prominent players in those markets. So the focus of our R&D today goes toward all development of niche molecules — molecules where, as you say, the number of competitors or players is smaller, or molecules with greater complexity in formulation; that's our focal point at present.

Vishal Manchanda

analyst
#102

But is this mostly centered on oral solids, or do you also have a team covering nasal sprays and...

Mark Saldanha

executive
#103

It applies to oral solids, and to tops, and to liquids, plus several other segments as well.

Vishal Manchanda

analyst
#104

My apologies.

Mark Saldanha

executive
#105

It applies to topicals, it applies to liquids, and it applies to several other segments as well.

Vishal Manchanda

analyst
#106

Understood. Alright, so as for your revenue, is it all generated by your own manufacturing, or do you also depend on contract manufacturing for some portion?

Mark Saldanha

executive
#107

No. I mean, clearly our facilities are spread across the U.S., the U.K., and India — and I'd say the vast majority of that, something like 98% or 99%, is produced at our own plants.

Vishal Manchanda

analyst
#108

Right, I believe your presentation pointed out a couple of nasal sprays that you've brought to market in Australia — I think it was 1 nasal spray or 2 nasal sprays. So, are those made in-house, or are they outsourced?

Mark Saldanha

executive
#109

No, those aren't in-house at the moment, though they will be shortly. As of today, however, they are not in-house.

Vishal Manchanda

analyst
#110

All right. And regarding the manufacturing assets you're also aiming to acquire — is there a particular dosage form you'd be focused on? Or would it again lean more toward capacities for manufacturing oral solids?

Mark Saldanha

executive
#111

We're looking at various dosage forms depending on what we think our capacity can essentially fill up, and fill up quickly. But regardless of which dosage forms we move into, we'll always make sure there's a solid oral block in and around that location. Because ultimately, nothing rivals solid oral dosage forms.

Vishal Manchanda

analyst
#112

Got it. And you mentioned that we're likely seeing a few capacity limits when it comes to oral solids—did I get that right? Or is that not the case?

Mark Saldanha

executive
#113

Nope. At this point we're fine for the coming 2 years — 2 to 3 years — though you're always going to want more capacity.

Operator

operator
#114

Our following question is from Harshil with ASK Wealth Advisors.

Analyst

analyst
#115

Sir, I actually just missed out on one point — I wanted to get your views on it. So on the margins front, we've done a good 23% in Q2. And toward the end of the full year, we had guided somewhere around 21% or something. But sir, is there a possibility that we could kind of have something higher than 21% 27?

Mark Saldanha

executive
#116

That could happen, sure. To get there, though, you'd need to phone the President and halt the war. That's really all it takes.

Operator

operator
#117

Ladies and gentlemen, since no one else has questions, that brings the Q&A portion to a close. At this point I'll turn the conference back to management for their closing remarks.

Mark Saldanha

executive
#118

Thanks to each of you for taking the time — your valuable time — to join this conference call. I'd like to wish you a good evening and to stay safe. Thank you so much.

Operator

operator
#119

Thanks. That brings this call to a close on behalf of Marksans Pharma and Systematix Institutional Equities Limited. We appreciate your participation. Your lines can be disconnected now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Marksans Pharma Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Marksans Pharma Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Marksans Pharma Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.